Carposekkur 175 mg/43,75 mg/200 mg Filmdragerad tablett Швеция - шведский - Läkemedelsverket (Medical Products Agency)

carposekkur 175 mg/43,75 mg/200 mg filmdragerad tablett

sigillata ltd - entakapon; karbidopa (monohydrat); levodopa - filmdragerad tablett - 175 mg/43,75 mg/200 mg - sojalecitin hjälpämne; entakapon 200 mg aktiv substans; karbidopa (monohydrat) 47,25 mg aktiv substans; levodopa 175 mg aktiv substans - dekarboxylashämmare och comt-hämmare

Carposekkur 200 mg/50 mg/200 mg Filmdragerad tablett Швеция - шведский - Läkemedelsverket (Medical Products Agency)

carposekkur 200 mg/50 mg/200 mg filmdragerad tablett

sigillata ltd - entakapon; karbidopa (monohydrat); levodopa - filmdragerad tablett - 200 mg/50 mg/200 mg - sojalecitin hjälpämne; karbidopa (monohydrat) 54 mg aktiv substans; levodopa 200 mg aktiv substans; entakapon 200 mg aktiv substans - dekarboxylashämmare och comt-hämmare

Carposekkur 50 mg/12,5 mg/200 mg Filmdragerad tablett Швеция - шведский - Läkemedelsverket (Medical Products Agency)

carposekkur 50 mg/12,5 mg/200 mg filmdragerad tablett

sigillata ltd - entakapon; karbidopa (monohydrat); levodopa - filmdragerad tablett - 50 mg/12,5 mg/200 mg - karbidopa (monohydrat) 13,5 mg aktiv substans; sojalecitin hjälpämne; entakapon 200 mg aktiv substans; levodopa 50 mg aktiv substans - dekarboxylashämmare och comt-hämmare

Carposekkur 75 mg/18,75 mg/200 mg Filmdragerad tablett Швеция - шведский - Läkemedelsverket (Medical Products Agency)

carposekkur 75 mg/18,75 mg/200 mg filmdragerad tablett

sigillata ltd - entakapon; karbidopa (monohydrat); levodopa - filmdragerad tablett - 75 mg/18,75 mg/200 mg - sojalecitin hjälpämne; entakapon 200 mg aktiv substans; levodopa 75 mg aktiv substans; karbidopa (monohydrat) 20,25 mg aktiv substans - dekarboxylashämmare och comt-hämmare

Metotrexat Astron 50 mg/ml Injektionsvätska, lösning i förfylld spruta Швеция - шведский - Läkemedelsverket (Medical Products Agency)

metotrexat astron 50 mg/ml injektionsvätska, lösning i förfylld spruta

astron research ltd - metotrexat - injektionsvätska, lösning i förfylld spruta - 50 mg/ml - metotrexat 50 mg aktiv substans

Jayempi Европейский союз - шведский - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - graftförkastning - immunsuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Ceftiofur N-vet 50 mg/ml Pulver och vätska till injektionsvätska, lösning Швеция - шведский - Läkemedelsverket (Medical Products Agency)

ceftiofur n-vet 50 mg/ml pulver och vätska till injektionsvätska, lösning

norbrook laboratories (ireland) limited - ceftiofurnatrium - pulver och vätska till injektionsvätska, lösning - 50 mg/ml - ceftiofurnatrium 52,1 mg aktiv substans - ceftiofur - nöt, svin

Spotinor vet 10 mg/ml Spot-on, lösning Швеция - шведский - Läkemedelsverket (Medical Products Agency)

spotinor vet 10 mg/ml spot-on, lösning

norbrook laboratories (ireland) limited - deltametrin - spot-on, lösning - 10 mg/ml - deltametrin 10 mg aktiv substans - deltametrin - får, nöt

Norocarp 100 mg Tablett Швеция - шведский - Läkemedelsverket (Medical Products Agency)

norocarp 100 mg tablett

norbrook laboratories (ireland) limited - karprofen - tablett - 100 mg - natriumlaurilsulfat hjälpämne; tartrazin hjälpämne; laktosmonohydrat hjälpämne; karprofen 100 mg aktiv substans - carprofen - hund

Peptizole 370 mg/g Oral pasta Швеция - шведский - Läkemedelsverket (Medical Products Agency)

peptizole 370 mg/g oral pasta

norbrook laboratories limited - omeprazol - oral pasta - 370 mg/g - omeprazol 370 mg aktiv substans - omeprazol - häst